Evidence map›Paper›PMID 37759500›Full record

ArticleCells2023

Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer's Disease.

Marina Ulanova, Lucy Gloag, Andre Bongers, Chul-Kyu Kim, Hong Thien Kim Duong, Ha Na Kim, John Justin Gooding, Richard D Tilley, Joanna Biazik, Wei Wen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Marina UlanovaCentre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW 2052, Australia.
Lucy GloagFaculty of Science, School of Mathematical and Physical Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Andre BongersMark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW 2052, Australia.
Chul-Kyu KimCentre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW 2052, Australia.
Hong Thien Kim DuongSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.
Ha Na KimMolecular Surface Interaction Laboratory, Mark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW 2052, Australia.
John Justin GoodingSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-5398-0597
Richard D TilleyMark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW 2052, Australia.
Joanna BiazikMark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW 2052, Australia.
Wei WenCentre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW 2052, Australia.
Perminder S SachdevCentre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-9595-3220
Nady BraidyCentre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-0497-5572
UNSW Sydney · AUUniversity of Technology Sydney · AU

Funding

Australian Research Council Discovery Early Career Award DE170100628Australian Research Council Discovery Project DP190102659Australian Research Council Discovery Project DP200100143
6 · The paper itself

Abstract

Nanoparticle-based magnetic contrast agents have opened the potential for magnetic resonance imaging (MRI) to be used for early non-invasive diagnosis of Alzheimer's disease (AD). Accumulation of amyloid pathology in the brain has shown association with cognitive decline and tauopathy; hence, it is an effective biomarker for the early detection of AD. The aim of this study was to develop a biocompatible magnetic nanoparticle targeted to amyloid beta (A

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesContrast MediaMagnetic Iron Oxide NanoparticlesMagnetic Resonance ImagingSuccimerCell Line, TumorHumansAmyloid beta-PeptidesContrast MediaSuccimerAlzheimer’s diseasediagnosisiron nanoparticlesmagnetic resonance imaging

Identifiers

PMID37759500
PMCPMC10527350
OpenAlexW4386781420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.